This article is more than 5 years old. Information may no longer be current.
Juvéderm Volbella XC available to physicians for lip augmentation, perioral rhytids
Click Here to Manage Email Alerts
Allergan plc has announced that Juvéderm Volbella XC is now available to physicians and patients for lip augmentation and for correction of perioral rhytids in adults aged over 21 years.
Juvéderm Volbella XC injectable gel was found to be effective in increasing lip fullness and softening the appearance around the mouth of patients through one year in clinical trials, according to a press release.
“Our physician customers have told us perioral lines are difficult to treat and are also a top concern among patients,” David Moatazedi, senior vice president of U.S. Medical Aesthetics, stated in the release. “We developed a soft, smooth gel appropriate for adding subtle volume to the lips and softening the appearance of perioral lines to address the specific need.”
Juvéderm Volbella XC is formulated with Vycross, a proprietary filler technology that yields smooth products, according to the release.
Common adverse events observed during the clinical trials were temporary responses at the treatment site, including swelling, tenderness, bruising, firmness lumps and bumps, redness, pain dislocation, itching and dryness, with most resolving within 30 days, according to the release.
Allergan announced the FDA approval of marketing of Juvéderm Volbella XC for lip augmentation and correcting perioral rhytids in adults in June.
Physicians who have completed an online training program are able to purchase Juvéderm Volbella XC, Allergan reported.
Reference: www.allergan.com